No Data
No Data
Botanix Pharmaceuticals Posts Wider Fiscal H1 Loss, Lower Revenue
Botanix Pharmaceuticals Ltd: Appendix 4D and Half Year Report
Botanix Pharmaceuticals' Prescription Gel Commercial Launch Could Drive Stock Re-rating, Euroz Hartleys Says
5 ASX All Ords Shares Starting the New Year at 52-week Highs
Those Who Invested in Botanix Pharmaceuticals (ASX:BOT) Three Years Ago Are up 443%
Botanix Pharmaceuticals Says US Payer Group to Cover Its Excessive Sweat Medication; Shares Up 6%